Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 10.12 [8][9]. Core Views - The company reported a significant quarter-on-quarter improvement in 1Q25, with revenue of RMB 7.015 billion (-21.9% year-on-year, +11% quarter-on-quarter) and a net profit of RMB 1.48 billion (-8.4% year-on-year, +169% quarter-on-quarter) [1]. - The improvement is attributed to stable core business performance and the recognition of upfront payments from Lp(a) and MAT2A small molecule BD transactions [2]. - The company is expected to see quarterly revenue and profit growth throughout the year, with a conservative estimate of approximately RMB 4 billion in annual core profits [2]. - The EGFR ADC clinical trials are progressing rapidly both domestically and internationally, indicating strong potential for overseas expansion [3]. - The company has a robust pipeline with significant BD progress and innovative platforms, enhancing its potential for international collaboration [4]. Financial Forecast and Valuation - The company’s EPS is projected to be RMB 0.49, 0.50, and 0.57 for the years 2025, 2026, and 2027 respectively, with a target PE of 19 times for 2025 [5]. - The estimated revenue for 2025 is RMB 31.101 billion, with a net profit of RMB 5.694 billion [19]. - The report highlights a significant reduction in sales expense ratio from 33% in 1Q24 to 24% in 1Q25, indicating improved cost management [2]. Key Metrics - The company’s market capitalization is approximately HKD 87.769 billion, with a closing price of HKD 7.62 as of May 29 [9]. - The projected revenue growth rates for the upcoming years are 7.21%, 8.35%, and 8.10% for 2025, 2026, and 2027 respectively [20].

Group 1: Market Overview - The report indicates that the US court's ruling against imposing comprehensive tariffs has led to market optimism regarding the end of the trade war, resulting in a rise in US stock markets and a halt to the five-day decline in A-shares [2][3] - The Hang Seng Index opened lower but rebounded significantly, closing up 315 points or 1.4%, with notable increases in major blue-chip stocks such as Meituan, Alibaba, and JD.com [3] Group 2: Macroeconomic and Industry Dynamics - The Financial Secretary of Hong Kong, Paul Chan, expressed intentions to strengthen ties with the Middle East market, highlighting the potential for collaboration in various financial products, including bonds and derivatives, following the listing of the first Saudi Islamic bond ETF in Hong Kong [6] - The CEO of Hong Kong Exchanges and Clearing, Charles Li, noted the growing momentum for connectivity between Hong Kong and Middle Eastern markets, with significant cooperation already established across various sectors [7] Group 3: Company News - New World Development is in the process of securing an HKD 87.5 billion refinancing deal, which has garnered significant attention from Hong Kong bankers, with at least 12 banks agreeing to terms so far [10] - CSPC Pharmaceutical Group reported a year-on-year decrease of 8.36% in net profit for the first quarter, with total revenue down 21.91%, primarily due to the impact of government policies on drug pricing [11] - Meizhong Pharmaceutical announced a placement of 18.6 million new H-shares at a discount of 19.7% to raise HKD 100 million for various operational needs [12]

Core Viewpoint - The Hong Kong stock market is undergoing significant changes, with a focus on the AI industry and the influx of quality companies, which is expected to drive future growth and investment opportunities [2][4]. Group 1: Market Performance - The Hang Seng Index opened down 0.99%, while the Hang Seng Tech Index fell by 1.26% [1]. - The influx of capital from mainland China is strengthening pricing power in the Hong Kong market, with expectations of continued inflows [2]. Group 2: Investment Opportunities - The AI industry is anticipated to lead the Hong Kong stock market upward, benefiting from high capital expenditure and the accumulation of scarce assets [2]. - Quality Chinese assets are seen as a fundamental basis for the sustainable growth of the Hong Kong stock market [3]. - The valuation of Hong Kong stocks is recovering, with the Hang Seng Index's PE ratio rising from approximately 7.5 times to 10.5 times, indicating room for further appreciation compared to historical highs [3]. Group 3: IPO Trends - The Hong Kong IPO market is expected to see a significant revival in 2025, providing a crucial window for domestic companies to raise foreign capital [3]. - The trend of A-share companies listing in Hong Kong is driven by strategic overseas expansion, regulatory advantages, and improved liquidity in the Hong Kong market [4]. Group 4: Government Policies - The Hong Kong government has implemented several supportive policies for the stock market, including lowering stamp duties and optimizing trading mechanisms to enhance market liquidity and attractiveness [5].

Core Viewpoint - CICC maintains the earnings forecast for CSPC Pharmaceutical Group (01093) for 2025 and 2026, with a target price increase of 26.5% to HKD 8.60, indicating a potential upside of 12.9% from the current stock price [1] Financial Performance - The company reported Q1 2025 results: revenue of CNY 7.015 billion (including BD revenue of CNY 718 million), down 21.9% YoY, but up 10.9% QoQ; net profit attributable to shareholders was CNY 1.478 billion (down 8.4% YoY, up 168.7% QoQ), and core net profit was CNY 1.411 billion (down 18.2% YoY, up 106.2% QoQ), aligning with CICC's expectations [2] Business Segment Analysis - Q1 2025 finished drug business faced pressure, with revenue of CNY 5.500 billion (down 27.3% YoY); specific segments included: CNS revenue CNY 1.908 billion (down 29.5% YoY), oncology CNY 552 million (down 65.7% YoY), anti-infection CNY 922 million (down 31.8% YoY), cardiovascular CNY 411 million (down 42.9% YoY), respiratory CNY 326 million (down 30.3% YoY), digestive metabolism CNY 299 million (down 4.7% YoY), and other finished drug products CNY 364 million (down 6.8% YoY); raw material drug revenue for Vitamin C was CNY 608 million (up 25.0% YoY) [3] Cost and Profitability Metrics - The company achieved a gross margin of 67.1% in Q1 2025 (down 5.2 percentage points YoY); the sales expense ratio improved to 23.7% (down 9.3 percentage points YoY), while the management expense ratio was 3.3% (down 0.4 percentage points YoY); R&D expense ratio was 23.7% (up 8.2 percentage points YoY), with expectations for annual R&D expenses to exceed CNY 5.5 billion [4] Innovation and Future Prospects - The company is optimistic about the clinical data readouts for key innovative products and the successful execution of BD transactions; SYS6010 (EGFR ADC) is under exploration with multiple clinical trials ongoing, and the company anticipates more significant BD transactions this year to enhance shareholder returns [5]

港股医药股走强 石药集团涨近8% 智通财经5月30日电，截至发稿，石药集团(01093.HK)涨7.61%、康哲药业(00867.HK)涨5.85%、信达生 物(01801.HK)涨3.86%、凯莱英(06821.HK)涨2.33%。 ...

Individual Company News - Li Auto (02015.HK) reported a total revenue of 25.9 billion yuan for Q1 2025, representing a year-on-year increase of 1.1%. Adjusted net profit was 1 billion yuan, down 20.5% year-on-year [1] - Sihuan Pharmaceutical (01093.HK) is in discussions with potential partners regarding licensing and collaboration in drug development, production, and commercialization [1] - SANY International (00631.HK) achieved a net profit of 636 million yuan in Q1, a year-on-year increase of 30.6%, driven by significant revenue growth in large port machinery, oil and gas equipment, silicon energy products, and overseas mining vehicle sales [1] - Minxin Group (00222.HK) has jointly established a partnership to invest in a national-level specialized and innovative technology enterprise [1] - China Orient Group (00581.HK) reported an operating profit of approximately 199 million yuan for Q1 after deducting financial costs [1] Pharmaceutical Sector News - Jiahe Biotech (06998.HK) received approval from the Chinese National Medical Products Administration for the market launch of the new drug GB491 [2] - Fosun Pharma (02196.HK) had its registration application for the drug Luwomeitini approved by the National Medical Products Administration [2] - Yum China (09987.HK) entered into a share repurchase agreement for a total buyback amount of approximately 510 million USD for the second half of the year [2]

5月29日恒生指数上涨1.35%，南向资金全天合计成交金额为990.06亿港元，其中，买入成交516.94亿港 元，卖出成交473.12亿港元，合计净买入金额43.82亿港元。具体来看，港股通（深）累计成交金额 334.38亿港元，买入成交168.17亿港元，卖出成交166.21亿港元，合计净买入金额1.96亿港元；港股通 （沪）累计成交金额655.68亿港元，买入成交348.77亿港元，卖出成交306.91亿港元，合计净买入金额 41.86亿港元。 5月29日南向资金成交活跃股 | 代码 | 简称 | 成交金额（万港元） | 成交净买入（万港元） | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | 03690 | 美团-W | 712189.63 | 104396.29 | 6.62 | | 06060 | 众安在线 | 339810.30 | 75644.16 | 31.56 | | 01093 | 石药集团 | 202989.66 | 36597.45 | 11.73 | | 09992 | 泡泡玛特 | 192367.26 | 17803.28 | 4.31 ...

Group 1 - Several banks have suspended the issuance of 5-year large-denomination certificates of deposit (CDs), while 3-year CDs remain available but with limited quotas for certain clients [1] - The average selling price (ASP) of NAND Flash suppliers decreased by 15% quarter-on-quarter in Q1 2025, with total revenue for the top five brands dropping nearly 24% to $12.02 billion [1] - The global TV market saw a 2.4% year-on-year increase in shipment volume in Q1 2025, driven by stable demand in Western Europe and North America, along with government subsidies in China [1] Group 2 - The first domestic "liquid oxygen methane + stainless steel + sea soft landing recovery" rocket successfully completed its maiden sea flight recovery test, marking a significant technological breakthrough [2] - Zong Fuli has resigned as the legal representative of Xi'an Hengfeng Beverage Co., Ltd., with Zhu Lidan taking over the position [2] Group 3 - Kuaishou's Keling AI has launched a new 2.1 series model, offering competitive pricing for video generation, with 5-second videos costing as low as 20 inspiration points [3] - DJI has acquired land in Shenzhen for 2.287 billion yuan to establish a global headquarters for its smart aviation system industry ecosystem [3] Group 4 - Li Auto reported a net profit of 647 million yuan in Q1 2025, a year-on-year increase of 9.4%, with total revenue reaching 25.9 billion yuan [4] - Futu Holdings' Q1 2025 revenue was 4.695 billion HKD, a year-on-year increase of 81.1%, with net profit rising by 97.7% [4] Group 5 - CSPC Pharmaceutical Group reported a revenue of 7.015 billion yuan in Q1, a year-on-year decrease of 21.9% [5] - The former general manager of Pacific Securities' Haikou branch was fined for violating stock trading regulations, with a total trading amount exceeding 30 million yuan [5] Group 6 - China State Construction Engineering Corporation has recently won three major projects with a total value of 8.23 billion yuan [6] - Jiahuan Technology has been awarded a construction service project for China Mobile, with a total contract value of 2.185 billion yuan [7] Group 7 - Xiaogoods City’s wholly-owned subsidiary won a bid for a core land parcel in Hangzhou for 568.71 million yuan, planning to build two 14-story office buildings [8] Group 8 - The ChiNext index rose by 1.37% in a market rebound, with over 4,400 stocks increasing in value, and more than 100 stocks hitting the daily limit [9]

Core Viewpoint - Southbound capital saw a significant net inflow today, indicating renewed interest in the Hong Kong market, with the Hang Seng Index rebounding above 23,500 points, suggesting bullish sentiment from various investors beyond just southbound funds [1][2]. Group 1: Southbound Capital Flow - Today's southbound capital transaction amounted to approximately 99.01 billion HKD, accounting for about 43.64% of the total turnover of the Hang Seng Index, showing a recovery in share compared to the previous day but still below the long-term average [1]. - The net inflow of southbound capital was around 4.38 billion HKD, with the Shanghai-Hong Kong Stock Connect contributing approximately 4.19 billion HKD and the Shenzhen-Hong Kong Stock Connect contributing about 0.20 billion HKD [2][6]. Group 2: Individual Stock Performance - Major net purchases included Meituan-W (03690.HK) with 1.04 billion HKD, ZhongAn Online (06060.HK) with 0.76 billion HKD, and CSPC Pharmaceutical Group (01093.HK) with 0.37 billion HKD, indicating strong interest in these stocks [3][4]. - Significant net sales were observed in Semiconductor Manufacturing International Corporation (00981.HK) with 0.56 billion HKD, Xiaomi Group-W (01810.HK) with 0.53 billion HKD, and XPeng Inc. (09868.HK) with 0.48 billion HKD, reflecting a shift in investor sentiment away from these companies [3][4]. Group 3: Stock Price Movements - Meituan-W experienced a price increase of 6.62%, with short-term funds accelerating their inflow, having accumulated 3.12 million shares over the past five days [4]. - ZhongAn Online surged by 31.56%, indicating a strong influx of short-term capital, with 0.77 million shares added in the last five days [4]. - CSPC Pharmaceutical Group rose by 11.73%, with a predominant inflow of short-term funds, accumulating 1.62 million shares over the past five days [4]. - In contrast, Semiconductor Manufacturing International Corporation saw a slight increase of 1.47%, but short-term funds continued to flow out, reducing holdings by 1.11 million shares [4].

Group 1 - The stock price of CSPC Pharmaceutical Group Limited (01093.HK) closed at HKD 7.620 on May 29, marking an increase of 11.73% from the previous trading day, with an intraday high of HKD 7.800, reaching a nearly one-year high [1] - The net capital inflow for the day was HKD 40,423.60 million, with a total inflow of HKD 167,151.474 million and outflow of HKD 126,727.872 million [1] - CSPC Pharmaceutical is a well-known pharmaceutical company listed in Hong Kong, established in 1994, and became a constituent of the Hang Seng Index in 2018, being the first pharmaceutical stock in the index [1] Group 2 - CSPC Pharmaceutical operates in two main business segments: finished drugs and active pharmaceutical ingredients, with a core development strategy focused on innovative drugs [1] - The company has a strong product portfolio in therapeutic areas such as neurological diseases, oncology, anti-infection, and cardiovascular diseases, with popular innovative products including 'Enbipu', 'Domis', 'Jin You Li', 'Ke Ai Li', and 'Xuan Ning' [1] - The active pharmaceutical ingredients include Vitamin C, antibiotics, and caffeine series, with the main production base located in Shijiazhuang, Hebei Province, China [1] Group 3 - CSPC Pharmaceutical has an international R&D team with research bases in Shijiazhuang, Shanghai, Beijing, and the United States, focusing on small molecule targeted drugs, nano drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and immunobiological drugs [2] - The "CSPC" brand has been recognized as one of the "Top 500 Most Valuable Brands in China" by the World Brand Lab for over ten consecutive years since 2004 [2] - The company actively participates in social responsibility initiatives, supporting various charitable activities during significant events such as SARS, the Indonesian tsunami, and major earthquakes, demonstrating a commitment to giving back to society [2]